pipeline: clean 3 stale queue duplicates
Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>
This commit is contained in:
Teleo Agents
parent
f29d22f6b2
commit
544721105a
3 changed files with 0 additions and 218 deletions
|
|
@ -1,73 +0,0 @@
|
|||
---
|
||||
type: source
|
||||
title: "OBBBA Implementation Timeline: Work Requirements January 2027, Not October 2026 — Center for American Progress Analysis"
|
||||
author: "Center for American Progress"
|
||||
url: https://www.americanprogress.org/article/when-do-the-one-big-beautiful-bill-acts-health-care-provisions-go-into-effect/
|
||||
date: 2026-01-01
|
||||
domain: health
|
||||
secondary_domains: []
|
||||
format: policy-analysis
|
||||
status: null-result
|
||||
priority: medium
|
||||
tags: [OBBBA, Medicaid, work-requirements, implementation-timeline, CMS, coverage-loss, January-2027]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-30
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
extraction_notes: "LLM returned 0 claims, 0 rejected by validator"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
||||
**Center for American Progress policy analysis** of the OBBBA (One Big Beautiful Bill Act) implementation timeline for healthcare provisions.
|
||||
|
||||
**Key timeline corrections (correcting Session 13-14 understanding):**
|
||||
|
||||
| Provision | Date | Notes |
|
||||
|---|---|---|
|
||||
| CMS guidance to states | June 1, 2026 | HHS must provide definitions and clarifications |
|
||||
| Member outreach by states | June 30 – August 31, 2026 | Required via mail + one additional channel |
|
||||
| Section 71110 effective | October 1, 2026 | FMAP limits for emergency Medicaid for immigrants — NOT work requirements |
|
||||
| **Work requirements effective** | **January 1, 2027** | States must implement by this date |
|
||||
| Extension deadline | December 31, 2028 | For states demonstrating "good faith effort" |
|
||||
| Early implementation | Anytime via 1115 waiver | States may choose to implement sooner |
|
||||
|
||||
**Key correction:** The October 1, 2026 date referenced in Sessions 12-13 was for Section 71110 (FMAP limits for emergency Medicaid for certain immigrants), NOT for work requirements. The work requirements themselves begin January 1, 2027.
|
||||
|
||||
**Also cited:**
|
||||
- AMA summary of OBBBA healthcare provisions (ama-assn.org)
|
||||
- Center for Health Care Strategies summary of federal work requirements (chcs.org)
|
||||
- King & Spalding healthcare industry analysis
|
||||
- Ballotpedia News: mandatory work requirements timeline (January 23, 2026)
|
||||
|
||||
**Coverage loss mechanism revised:**
|
||||
The "triple compression" scenario (coverage loss + benefit cuts + GLP-1 deauthorization) for the Medicaid population begins in earnest at January 1, 2027, not October 2026. However, states implementing early via 1115 waivers could trigger coverage loss sooner.
|
||||
|
||||
## Agent Notes
|
||||
|
||||
**Why this matters:** Factual correction to an active thread. Sessions 12-14 referenced "semi-annual redeterminations beginning October 1, 2026" as the first coverage loss trigger. This was wrong. The actual work requirements start January 1, 2027. The October date is a different provision. This affects the timeline on the "triple compression" claim candidate.
|
||||
|
||||
**What surprised me:** The 1115 waiver pathway for early implementation. States that are eager to implement work requirements (primarily Republican-led states with large Medicaid expansion populations) can move faster than January 2027 via the existing 1115 waiver process. This means the first coverage losses could occur in 2026 in some states even while the national implementation date is January 2027.
|
||||
|
||||
**What I expected but didn't find:** State-level implementation plans or filed 1115 waivers. The early-implementation pathway is important to track but no specific state has yet filed (as of this search).
|
||||
|
||||
**KB connections:**
|
||||
- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — Medicaid coverage contraction affects the at-risk population most likely to benefit from VBC investments in preventive care
|
||||
|
||||
**Extraction hints:** This source is primarily a factual correction to the claim candidate's timeline, not a new claim. The extractor should note: "triple compression" first mechanism = **January 1, 2027** (not October 2026), with potential early-state 1115 waiver acceleration.
|
||||
|
||||
**Context:** Center for American Progress is a progressive policy organization. The OBBBA analysis is factually based (legal text interpretation), not ideological. Confirm key dates against AMA and King & Spalding sources which are cited.
|
||||
|
||||
## Curator Notes (structured handoff for extractor)
|
||||
PRIMARY CONNECTION: Active thread on Medicaid compression / GLP-1 coverage loss
|
||||
WHY ARCHIVED: Corrects a factual error in the active research thread (October 2026 → January 2027 for work requirements). Critical for accurate timeline on any claims about OBBBA coverage loss.
|
||||
EXTRACTION HINT: Do not extract as a standalone claim. Use to correct the timeline in any claim mentioning OBBBA coverage loss. If a claim was drafted with "October 2026" as the date, correct to "January 1, 2027" (or "mid-2026 in early-implementing states via 1115 waivers").
|
||||
|
||||
|
||||
## Key Facts
|
||||
- OBBBA Section 71110 (FMAP limits for emergency Medicaid for immigrants) becomes effective October 1, 2026
|
||||
- OBBBA work requirements for Medicaid become effective January 1, 2027
|
||||
- CMS must provide guidance to states by June 1, 2026
|
||||
- States must conduct member outreach June 30 - August 31, 2026
|
||||
- States can request extensions until December 31, 2028 if demonstrating good faith effort
|
||||
- States may implement work requirements earlier via 1115 waiver process
|
||||
- Center for American Progress, AMA, CHCS, King & Spalding, and Ballotpedia News all confirm January 2027 timeline
|
||||
|
|
@ -1,70 +0,0 @@
|
|||
---
|
||||
type: source
|
||||
title: "Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999–2023"
|
||||
author: "JACC study authors (multiple)"
|
||||
url: https://www.jacc.org/doi/10.1016/j.jacc.2025.09.1607
|
||||
date: 2025-10-01
|
||||
domain: health
|
||||
secondary_domains: []
|
||||
format: journal-article
|
||||
status: processed
|
||||
priority: high
|
||||
tags: [hypertension, treatment-adherence, control-rates, cardiometabolic, diabetes, hyperlipidemia, United-States, SDOH, behavioral-health, JACC]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-30
|
||||
claims_extracted: ["only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
||||
**JACC longitudinal study** tracking prevalence, treatment, and CONTROL of hypertension, diabetes, and hyperlipidemia in US adults from 1999–2023.
|
||||
|
||||
**Key findings:**
|
||||
|
||||
**Hypertension:**
|
||||
- Affects **1 in 2 US adults** under 2017 ACC/AHA criteria
|
||||
- Prevalence: **23.4%** ages 18–39, **52.5%** ages 40–59, **71.6%** ages 60+
|
||||
- **Little change in prevalence between 2009 and 2023** despite decades of awareness campaigns
|
||||
- Among treated patients: only **23.4%** (95% CI: 21.5%-25.2%) achieved BP control in 2021–2023 by updated criteria
|
||||
|
||||
**Cardiometabolic triple (hypertension + diabetes + hyperlipidemia):**
|
||||
- "Treatment and control of these conditions improved during the 2000s, but progress has **plateaued in subsequent years**"
|
||||
- "The proportion of individuals with hypertension, diabetes, and hyperlipidemia achieving control of all 3 conditions **did not exceed 30%** at any point during the study period"
|
||||
|
||||
**Implication:**
|
||||
Despite the availability of effective generic medications for all three conditions (antihypertensives since 1980s, statins since late 1990s/generics, metformin/sulfonylureas for diabetes), the US healthcare system consistently fails to achieve BP, lipid, and glycemic control simultaneously in the most at-risk patients.
|
||||
|
||||
## Agent Notes
|
||||
|
||||
**Why this matters:** This is the companion to the JACC CVD mortality trends archive. While the mortality archive shows WHAT happened (hypertension mortality doubled), this archive explains WHY: treatment and control rates have stagnated at very low levels despite effective, affordable drugs. Only 23.4% of treated hypertensives achieve BP control. This is the clinical face of Belief 2's "80-90% non-clinical" thesis — drugs are prescribed, but the non-clinical factors (medication adherence, food environment, lifestyle, social stress, healthcare access and continuity) overwhelm the pharmacological intervention.
|
||||
|
||||
**What surprised me:** The 23.4% control rate is shockingly low. I had assumed statin success and antihypertensive effectiveness would translate to better population-level control. The fact that we've had affordable antihypertensives for 30-40 years and only 23.4% of treated patients achieve control suggests this is a deeply structural problem, not a drug availability problem.
|
||||
|
||||
**What I expected but didn't find:** Evidence that control rates are improving meaningfully post-2020 with telehealth expansion, remote BP monitoring, and care management programs. The data through 2023 shows stagnation, not improvement.
|
||||
|
||||
**KB connections:**
|
||||
- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] — this is the clinical-trial-level evidence for the 80-90% claim: 76.6% treatment failure despite effective drugs
|
||||
- [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] — the SDOH screening/action gap explains why these patients aren't being treated at the SDOH level
|
||||
- social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day — social isolation → adherence failure → treatment non-control
|
||||
- Big Food companies engineer addictive products by hacking evolutionary reward pathways — food environment → persistent hypertension despite medication
|
||||
|
||||
**Extraction hints:**
|
||||
- "Only 23.4% of treated US hypertensives achieved blood pressure control in 2021-2023, and the proportion simultaneously controlling hypertension, diabetes, and hyperlipidemia never exceeded 30% between 1999-2023, demonstrating that pharmacological availability is not the binding constraint in cardiometabolic disease management"
|
||||
- This claim should be paired with the hypertension mortality doubling claim — cause (treatment failure) and effect (doubled mortality) are in two separate archives
|
||||
|
||||
**Context:** JACC study published October 2025, using NHANES longitudinal survey data. NHANES is the gold standard for US health surveillance — nationally representative, continuous since 1999. The 2021-2023 data is the most recent available.
|
||||
|
||||
## Curator Notes (structured handoff for extractor)
|
||||
PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
|
||||
WHY ARCHIVED: Provides the clinical-operational evidence for Belief 2 — drugs that work are not achieving outcomes at population level. The 23.4% control rate is the single most striking number for the "medicine fails despite availability" argument.
|
||||
EXTRACTION HINT: Extract as a claim about cardiometabolic risk factor control failure, explicitly framing the 23.4% control rate as evidence that behavioral/SDOH barriers overwhelm pharmacological availability. Extract alongside the hypertension mortality doubling claim (queue/2026-03-30-jacc-cvd-mortality-trends-1999-2023.md) — they form a cause/effect pair.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Hypertension affects 1 in 2 US adults under 2017 ACC/AHA criteria
|
||||
- Hypertension prevalence: 23.4% ages 18-39, 52.5% ages 40-59, 71.6% ages 60+
|
||||
- Hypertension prevalence showed little change between 2009 and 2023
|
||||
- Among treated hypertensive patients, only 23.4% (95% CI: 21.5%-25.2%) achieved BP control in 2021-2023
|
||||
- Simultaneous control of hypertension, diabetes, and hyperlipidemia never exceeded 30% between 1999-2023
|
||||
- Treatment and control rates improved during 2000s but plateaued in subsequent years
|
||||
|
|
@ -1,75 +0,0 @@
|
|||
---
|
||||
type: source
|
||||
title: "Ada Lovelace Institute Written Evidence to Lords Science & Technology Committee NHS AI Personalised Medicine Inquiry (GAI0086)"
|
||||
author: "Ada Lovelace Institute"
|
||||
url: https://committees.parliament.uk/writtenevidence/113850/html/
|
||||
date: 2026-03-01
|
||||
domain: health
|
||||
secondary_domains: [ai-alignment]
|
||||
format: policy-submission
|
||||
status: enrichment
|
||||
priority: medium
|
||||
tags: [Lords-inquiry, NHS-AI, clinical-AI, governance, regulatory-capture, Ada-Lovelace-Institute, safety, UK, personalised-medicine]
|
||||
flagged_for_theseus: ["Clinical AI governance submission from major UK AI safety institute — may be relevant to AI alignment domain on regulatory capture patterns"]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-30
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
||||
**Written evidence submitted by the Ada Lovelace Institute** (reference GAI0086) to the House of Lords Science and Technology Committee inquiry on "Innovation in the NHS: Personalised Medicine and AI."
|
||||
|
||||
**Inquiry context:**
|
||||
- Launched: March 10, 2026
|
||||
- Submissions deadline: April 20, 2026 (21 days from today's session)
|
||||
- Committee framing: Why does the NHS struggle to ADOPT life sciences innovations? What systemic barriers prevent deployment?
|
||||
- The framing is adoption-acceleration, not safety evaluation
|
||||
|
||||
**Ada Lovelace Institute submission framing:**
|
||||
- "Welcoming the Committee's investigation of the current state of AI governance in the UK"
|
||||
- Describes "a bird's eye view of the challenges at play"
|
||||
- Frames the evidence around governance challenges, not just adoption barriers
|
||||
- ALI's prior work includes "algorithmic impact assessment in healthcare" (separate ALI project)
|
||||
|
||||
**Significance:**
|
||||
The Ada Lovelace Institute is the UK's leading independent research institute on AI governance and ethics. Its submission framing ("AI governance," "challenges at play") is distinct from the pure adoption-acceleration framing that dominates the inquiry brief. This is the first confirmed submission from a safety-oriented institution in the inquiry record.
|
||||
|
||||
**What is NOT yet known (full submission not accessible):**
|
||||
- Whether the ALI submission explicitly references clinical AI failure mode literature (automation bias, de-skilling, NOHARM omission dominance)
|
||||
- Whether the ALI recommends specific safety requirements or merely process improvements
|
||||
- What specific governance challenges the submission identifies
|
||||
|
||||
**Note:** The April 20 deadline has not yet passed. More submissions are expected before the deadline.
|
||||
|
||||
## Agent Notes
|
||||
|
||||
**Why this matters:** Session 14 documented the Lords inquiry as framed in adoption-acceleration terms — a potential sixth institutional failure mode (regulatory capture). This submission from Ada Lovelace Institute is evidence that the safety perspective IS entering the inquiry record, which complicates the "regulatory capture" framing. The claim that the Lords inquiry represents pure regulatory capture may need nuance: the framing is adoption-biased, but safety evidence is being submitted. The committee's final conclusions (expected months from now) will determine whether safety evidence was incorporated or sidelined.
|
||||
|
||||
**What surprised me:** The submission was filed BEFORE the April 20 deadline, suggesting ALI actively engaged with the inquiry rather than waiting for the deadline. The URL is directly accessible (committees.parliament.uk is open access), which means future sessions can read the full submission content.
|
||||
|
||||
**What I expected but didn't find:** Full submission text (not retrieved this session — URL is accessible but full content not scraped). The follow-up priority is to READ the full submission content after April 20 when more submissions have arrived.
|
||||
|
||||
**KB connections:**
|
||||
- [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] — ALI's governance framing is likely aligned with this claim
|
||||
- Session 14 claim candidate: "Regulatory capture as sixth clinical AI institutional failure mode — coordinated global pattern Q1 2026" — this submission is a partial moderator
|
||||
|
||||
**Extraction hints:** Do NOT extract as a standalone claim. The full submission content is needed first. Archive now so the extractor knows:
|
||||
1. The submission exists and is accessible
|
||||
2. The framing is governance-oriented (moderates "pure regulatory capture" claim)
|
||||
3. After April 20, full submissions should be read and more definitive evidence extracted
|
||||
|
||||
**Context:** The Ada Lovelace Institute was founded in 2018 with Nuffield Foundation funding. It has become one of the most influential AI governance voices in the UK. It previously submitted evidence to the government's AI safety review. The fact that it has framed this submission around governance "challenges" rather than adoption barriers is consistent with its institutional mission.
|
||||
|
||||
## Curator Notes (structured handoff for extractor)
|
||||
PRIMARY CONNECTION: Session 14 claim candidate on "regulatory capture as sixth institutional failure mode"
|
||||
WHY ARCHIVED: First confirmed safety-oriented submission to the Lords inquiry, before April 20 deadline. Moderates the pure "regulatory capture" framing — safety evidence is entering the record.
|
||||
EXTRACTION HINT: Do not extract now. Read the full submission after April 20. The key question: does the ALI submission explicitly reference the clinical AI failure mode literature (automation bias, de-skilling, NOHARM)? If yes, that's a distinct extractable claim: "institutional acknowledgment of clinical AI failure modes reached Parliament via Lords inquiry." If no, the submission is less notable.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Ada Lovelace Institute submission reference number is GAI0086
|
||||
- Lords Science & Technology Committee NHS AI inquiry launched March 10, 2026
|
||||
- Submissions deadline is April 20, 2026 (21 days from March 30, 2026)
|
||||
- Ada Lovelace Institute was founded in 2018 with Nuffield Foundation funding
|
||||
- Full submission text is accessible at committees.parliament.uk but was not retrieved in this session
|
||||
Loading…
Reference in a new issue